DE60021354D1 - Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung - Google Patents

Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung

Info

Publication number
DE60021354D1
DE60021354D1 DE60021354T DE60021354T DE60021354D1 DE 60021354 D1 DE60021354 D1 DE 60021354D1 DE 60021354 T DE60021354 T DE 60021354T DE 60021354 T DE60021354 T DE 60021354T DE 60021354 D1 DE60021354 D1 DE 60021354D1
Authority
DE
Germany
Prior art keywords
cropped
polynucleotides
preparing
same
proportion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60021354T
Other languages
English (en)
Other versions
DE60021354T2 (de
Inventor
Shinji Matsuyama
Kouichi Ishiyama
Junzo Seki
Tadaaki Ohgi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of DE60021354D1 publication Critical patent/DE60021354D1/de
Publication of DE60021354T2 publication Critical patent/DE60021354T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60021354T 1999-02-15 2000-02-14 Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung Expired - Fee Related DE60021354T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3596399 1999-02-15
JP3596399 1999-02-15
PCT/JP2000/000778 WO2000047601A1 (fr) 1999-02-15 2000-02-14 Polynucleotides a chaine raccourcie et procede de preparation correspondant

Publications (2)

Publication Number Publication Date
DE60021354D1 true DE60021354D1 (de) 2005-08-25
DE60021354T2 DE60021354T2 (de) 2006-04-27

Family

ID=12456623

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021354T Expired - Fee Related DE60021354T2 (de) 1999-02-15 2000-02-14 Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung

Country Status (14)

Country Link
US (2) US6780429B1 (de)
EP (1) EP1153931B1 (de)
KR (1) KR100455814B1 (de)
CN (1) CN1194002C (de)
AT (1) ATE299885T1 (de)
AU (1) AU2460900A (de)
BR (1) BR0008227A (de)
CA (1) CA2359674A1 (de)
DE (1) DE60021354T2 (de)
ID (1) ID29546A (de)
NO (1) NO20013941L (de)
RU (1) RU2238279C2 (de)
WO (1) WO2000047601A1 (de)
ZA (1) ZA200106701B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20010053763A1 (en) * 1998-12-02 2001-12-20 Andrew Salzman Method and composition for modulating an immune response
US20060166315A1 (en) * 2002-12-26 2006-07-27 Masatoshi Murai Process for producing pnpase
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
CA2722589A1 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
EP2116602A1 (de) 2008-05-07 2009-11-11 Institut Gustave Roussy Kombinationsprodukte zur Behandlung von Krebs
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
CA2792258A1 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
US9814740B2 (en) 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
CA2876150A1 (en) 2012-06-08 2013-12-12 The Johns Hopkins University Compostions and methods for cancer immunotherapy
US9816095B2 (en) 2012-12-06 2017-11-14 Kyowa Hakko Bio Co., Ltd. Double-stranded ribonucleic acid for adjuvants
CA2886456A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
PE20160167A1 (es) 2013-04-29 2016-04-21 Sloan Kettering Inst Cancer Composiciones y metodos para alterar la senalizacion del segundo mensajero
US20140329889A1 (en) * 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
EP3027227A4 (de) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Stachelkristalle und modulatoren
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3666646A (en) 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
US5298614A (en) * 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
GB2207138B (en) * 1987-07-03 1992-02-05 Nippon Shinyaku Co Ltd Preparation of nucleic acid derivatives.
DE69424406T2 (de) * 1993-02-19 2000-10-26 Nippon Shinyaku Co Ltd Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments

Also Published As

Publication number Publication date
RU2238279C2 (ru) 2004-10-20
BR0008227A (pt) 2001-10-30
DE60021354T2 (de) 2006-04-27
KR20020013500A (ko) 2002-02-20
CN1340055A (zh) 2002-03-13
WO2000047601A1 (fr) 2000-08-17
US7223857B2 (en) 2007-05-29
ID29546A (id) 2001-09-06
NO20013941D0 (no) 2001-08-14
KR100455814B1 (ko) 2004-11-06
CN1194002C (zh) 2005-03-23
NO20013941L (no) 2001-08-14
CA2359674A1 (en) 2000-08-17
US20040235044A1 (en) 2004-11-25
ZA200106701B (en) 2002-11-14
AU2460900A (en) 2000-08-29
ATE299885T1 (de) 2005-08-15
US6780429B1 (en) 2004-08-24
EP1153931A1 (de) 2001-11-14
EP1153931B1 (de) 2005-07-20
EP1153931A4 (de) 2002-07-17

Similar Documents

Publication Publication Date Title
DE60021354D1 (de) Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
DE3789878T2 (de) 8-Alkoxychinolinkarbonsäure und Salze davon, die sich durch selektive Toxizität auszeichnen, und Verfahren zu ihrer Herstellung.
DE69230967T2 (de) Verfahren zur herstellung von 2,6-naphthalindicarbonsäure
DE68907320D1 (de) Verfahren zur herstellung von modifizierten polypropylen-zusammensetzungen.
DE3674582D1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylidid-hydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
DE69800805T2 (de) Verfahren zur herstellung chiraler 3,4-epoxybuttersäure und ihrer salze
DE69419041T2 (de) Verfahren zur herstellung von photochromen annelierten spiro[indolin-[2,3']-benzoxazin]verbindungen
DE69901519T2 (de) Verfahren zur Herstellung von 2,2'-bis (Hydroxymethyl)alkansäure
DE3768426D1 (de) Verfahren zur herstellung von 4,4'-biphenyldicarbonsaeure.
DE59006645D1 (de) Verfahren zur kontinuierlichen herstellung von 3,3'-dichlor-benzidin-dihidrochlorid.
DE50006245D1 (de) Verfahren zur herstellung von (1,1':4',1'')-terphenylvebindungen
DE59705787D1 (de) Verfahren zur herstellung von n,n'-dialkylperylen-3,4,9,10-tetracarbonsäurediimiden
DE69514122D1 (de) Lösungsmittelfreies verfahren zur herstellung von 2,6 difluorbenzonitril
DE58904175D1 (de) Verfahren zur herstellung von 4,4'-dihalogeno-biphenylen.
DE69510798T2 (de) Verfahren zur herstellung von kalziumsalzen von [s,s]-äthylendiamin- n,n'-dibernsteinsäure
DE59611076D1 (de) Verfahren zur herstellung von 5,6-dihydro-1,3-oxazinen
DE3770059D1 (de) Verfahren zur herstellung von 4,4'-bis-phenol.
DE3874496D1 (de) Verfahren zur herstellung von 4,4'-dibrombiphenyl.
AT382617B (de) Verfahren zur herstellung des neuen 17, 18 dehydroapovincaminol - 3',4',5' trimethoxybenzoats und seiner saeureadditionssalze
DE69012103D1 (de) Verfahren zur herstellung von 4,4'-diisopropylbiphenyl.
DE59203960D1 (de) Verfahren zur Herstellung von reinem 3,3',4,4'-Tetraaminobiphenyl.
DE59806017D1 (de) Verfahren zur Herstellung von 3,3-Dimethylbuttersäure
DE69825325D1 (de) Verfahren zur Herstellung von 3,3',5,5'-Tetra-t-Butylbiphenol
DE60115538D1 (de) Verfahren zur Herstellung von hochreinen 5,5'-bi-1H-Tetrazoldiammoniumsalzen
DE69500601T2 (de) Verfahren zur Herstellung von Dianthrachinon-N,N'-dihydroazin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee